Key points from article :
Cambrian Biopharma raised $60 million in private financing to develop medicines to extend healthy lifespan.
“Unique operational strategy” is called DisCo, or distributed drug discovery company.
“...we really need companies that can move fast with a lot of capital,” James Peyer, CEO and Co-Founder of Cambrian.
Nine hallmarks of aging, including cellular senescence, sustained tissue inflammation and mitochondrial dysfunction.
Breakthroughs in immunology, genomics and epigenetics, and technologies from gene editing to new stem cell therapies.
Plans to tackle intracellular dysfunction, cellular dysfunction and tissue level dysfunction.
“Over the next decade, Cambrian aims to detect and prevent aging-related diseases,” - Peyer.
While in stealth mode, the company raised $60 million from a syndicate of long-term investors.
14 novel therapies under development within its stable of companies.
“We are proud to announce that with Sensei, there was a $600 million longevity IPO this year,” - Peyer.
